Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1370 participants.

Also called NCT06470022

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,370 participants (enrolled count) (from the registry)
Sponsor
Christian Juhl Terkelsen (from the registry)
Registry
  • NCT NCT06470022
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06470022. Randomized; no masking; primary purpose treatment. Start 2024-08-09 (actual); primary completion 2027-07-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.
Acronym
COMPARE-TAVI
Condition
Aortic Stenosis
Intervention (Device)
Medtronic Evolut FX
Intervention (Device)
Edwards Sapien 3 Ultra Resilia
Lead sponsor
Christian Juhl Terkelsen (class: other)
Collaborator
Department of Clinical Epidemiology, Aarhus University, DK-8200 Aarhus N, Denmark (class: not stated)

Record details

Record id
cardio:ct-nct06470022
Content hash
32f9223d74990672be795bd3050e5cd84f2be49180f850050be35edded28474c